BIOMERIEUX CORPORATE SESSION Advancing patient experience and the importance of QA/QC for autologous CAR T-cell therapy
Wednesday, May 31, 2023 12:00 PM - 01:00 PM
Room 242B
Corporate Session
Advancing patient experience and the importance of QA/QC for autologous CAR T-cell therapy
Chair
Mark Miller, MD, Chief Medical Officer, bioMérieux, France
Speakers
James Flament, Director, Head of QC EU, Kite Pharma, the Netherlands
Weiyun Ai, MD, PhD, Clinical Professor of Medicine - American Board of Medical Oncology – University of California, San Francisco - Division of Hematology and Oncology, USA
In individualized therapies, a patient is not just the recipient of a drug product. The patient is the starting point of the product. CAR T-cell therapy products require manipulation of living cells and extensive quality control tests. Industry together with healthcare professionals (HCPs) are continuously making efforts to reduce the time from bench to bedside, so that eligible patients can receive these innovative treatments.
In this symposium, an industry expert as well as a clinician will provide their perspectives on:
1) James Flament, Kite Pharma:
How a world leader in engineered CAR T-cell therapy is facing Quality Assurance / Quality Control (QA/QC) challenges for autologous CAR T-cell therapy products: timelines, process, quality attributes, equipment, regulatory aspects, skilled staff etc.
2) Weiyun Ai, MD, PhD, Clinical Professor of Medicine:
How HCPs are facing patient management challenges like accessibility, treatment planning, clinical condition, patient preparation, follow up, coordination with other stakeholders etc
Chair
Mark Miller, MD, Chief Medical Officer, bioMérieux, France
Speakers
James Flament, Director, Head of QC EU, Kite Pharma, the Netherlands
Weiyun Ai, MD, PhD, Clinical Professor of Medicine - American Board of Medical Oncology – University of California, San Francisco - Division of Hematology and Oncology, USA
In individualized therapies, a patient is not just the recipient of a drug product. The patient is the starting point of the product. CAR T-cell therapy products require manipulation of living cells and extensive quality control tests. Industry together with healthcare professionals (HCPs) are continuously making efforts to reduce the time from bench to bedside, so that eligible patients can receive these innovative treatments.
In this symposium, an industry expert as well as a clinician will provide their perspectives on:
1) James Flament, Kite Pharma:
How a world leader in engineered CAR T-cell therapy is facing Quality Assurance / Quality Control (QA/QC) challenges for autologous CAR T-cell therapy products: timelines, process, quality attributes, equipment, regulatory aspects, skilled staff etc.
2) Weiyun Ai, MD, PhD, Clinical Professor of Medicine:
How HCPs are facing patient management challenges like accessibility, treatment planning, clinical condition, patient preparation, follow up, coordination with other stakeholders etc
Sponsored by:
